What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Aurelie Najm AurelieRheumo
3 years 6 months ago
🚨 Study on MTX and male fertility
Analysis of semen parameters in
🙋🏼♂️HC
🙋🏼♂️RA, PsA and PsO MTX naive
🙋🏼♂️Post MTX
Reassuring data as NO significant effect of MTX was observed on several semen parameters.
#EULAR2022 @RheumNow
OP0131 https://t.co/Fq32lzAMAx
TheDaoIndex KDAO2011
3 years 6 months ago
#Belimumab safety in pregnancy
EudraVigilance database retrospect study 47 preg: BEL stopped 1st trimester (group A) vs. cont'd (group B)
- no diff in fetal death
- more preterm birth/low birth weight, congenital malform'n in group A (not stat sig) #EULAR2022 @rheumnow POS0705 https://t.co/sLQ3MHNcWa
TheDaoIndex KDAO2011
3 years 6 months ago
#COVIDvaccine is effective in active and inactive #SLE disease. Noted reduced response for MMF, MTX, GC>10 mg/day. Threshold of B cells is 9+ cell/uL to have a vaccine response. Prof T Dorner #EULAR2022 @rheumnow https://t.co/qyNUZxMccD
Richard Conway RichardPAConway
3 years 6 months ago
RABBIT registry data on CV events with JAKi. Incidence rate low 0.41/100PY. No increase compared to TNFi RR 0.94 (0.39-2.38). No increase in high-risk group RR 0.90 (0.37-2.17). Reassuring with wide CI's. @RheumNow #EULAR2022 OP0135 https://t.co/vBSsnfeBoR https://t.co/iYDZsNwMye
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Hamroun S et al for the GR2 Cohort showed that age HR 1.22 and use of NSAIDs HR 3.01 in the pre-conception period was associated with a longer time to conception in women with SpA. Research is needed on continuous NSAID use in the preconception period #EULAR2022 @RheumNow OP0153 https://t.co/hl6jUlK5PN
Janet Pope Janetbirdope
3 years 6 months ago
#SLE responses with #anifrolimumab separate vs standard of care+placebo& LLDAS at 12 weeks-predictor was high Type I IFN (younger, ⬆️disease activity) but diff sig for response w #belimumab. At bedside diff to tell pts with various signatures apart. #EULAR2022 @RheumNow Dorner https://t.co/98Sb3MIEps
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#OP0143 #EULAR2022 We need to screen/monitor our patients with #lupus for infection. Amsterdam cohort (>200 pts) reported association of infection and flare. 50% were on steroid. Infection type did not influence flare @RheumNow https://t.co/Pxpx5hXLv9
Aurelie Najm AurelieRheumo
3 years 6 months ago
Dementia in RA associated w/
⚡️Large joint swelling HR 2
⚡️Any CVD HR 2.25
⚡️Anxiety HR 1.86
⚡️Depression HR 2.63
at any time during disease course in retrospective cohort 800+ pts
#EULAR2022 @RheumNow OP0134 @MyasoedovaElena https://t.co/MLweRMEZXE
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0135:
German RABBIT 🐇 Registry:
⭐️ Observational, 46% Tofa, 54% Bari
No increased rate of CVD in JAK vs TNF inhibitor
🚨Unlike the ORAL Surveillance
@RheumNow https://t.co/O4IXg22Ybc
Dr. Antoni Chan synovialjoints
3 years 6 months ago
How many and quickly does nr-AxSpA progress to r-AxSpA? Poddubnyy et al for the PROOF study showed that 16% of nr-AxSpA pts progressed to r-AxSpA within 5 years, mean time to radiographic progression was 2.4 years #EULAR2022 @RheumNow OP0149 https://t.co/KTC8Xkt4ey
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Good morning from Copenhagen. Starting the day with looking at imaging in SpA, review of posters, vaccination, lupus nephritis and auto inflammatory disease #EULAR2022 @RheumNow https://t.co/aPEkLjDaK7
TheDaoIndex KDAO2011
3 years 6 months ago
Another promising drug for #SLE! Monoclonal Ab to BDCA2 ; phase II study noted improvement in joint manifestation but not impressive in cutaneous dz. - Prof T Dorner #EULAR2022 @rheumnow https://t.co/eKwQyomJUD
Janet Pope Janetbirdope
3 years 6 months ago
#ClinicalPearl 2/3 of pts with #SLE have Type 1 interferon signature. So, 1/3 of #lupus is NOT driven by this pathway. Importance may be what is targeted in each pt but doesn’t necessarily predict response to #anifrolimumab #EULAR2022 @eular_org @RheumNow T Dorner SLE session https://t.co/vMOC8yGJ2V
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0136:
PROTECT-RA Cohort - 150 pts established RA
Cholesterol loading capacity (CLC) on macrophages
⭐️High CLC correlates with CV events
⭐️bDMARD use affects CLC
@RheumNow https://t.co/9ngaH9yUI7
David Liew drdavidliew
3 years 6 months ago
Mortality after PMR:
looking at 35y follow-up of a cohort in Norway,
apparent higher mortality for women (vs men, general population) decades after.
Is this real? Treatment related?
My wild guess: sarcopenia kills.
Thoughts @Sarah_L_Mackie & tagged?
OP0181 #EULAR2022 @RheumNow https://t.co/k7p9jNfW5s
Poster Hall